<DOC>
	<DOCNO>NCT02610010</DOCNO>
	<brief_summary>A prior phase III randomize trial show considerable survival benefit combine treatment cisplatin-based concurrent chemotherapy two-dimensional conventional radiotherapy ( 2DCRT ) patient stage II ( Chinese 1992 stag system ) nasopharyngeal carcinoma . However , since intensity-modulated radiotherapy ( IMRT ) know superior 2DCRT local control , progression free survival even overall survival , pivotal question whether stage II [ T1N1M0 T2N0-1M0 , base 2010 International Union Cancer/American Joint Committee Cancer ( UICC/AJCC ) stag system ] patient still obtain significant benefit additional concurrent chemotherapy IMRT era . The investigator ' retrospective study ( PMID:26528755 ) indicate low risk nasopharyngeal carcinoma ( T1N1M0 , T2N0-1M0 T3N0M0 , 2010 UICC/AJCC stag system ) patient underwent IMRT could benefit cisplatin-based concurrent chemotherapy . Therefore , investigator perform randomize controlled trial address question , prudent assumption IMRT alone inferior IMRT plus concurrent chemotherapy stage II patient .</brief_summary>
	<brief_title>Intensity-modulated Radiotherapy With Without Concurrent Chemotherapy Stage II Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Eligible patient randomly assign receive intensity-modulated radiotherapy ( IMRT ) alone IMRT plus concurrent chemotherapy . IMRT give 2.0-2.30 Gy per fraction five daily fraction per week 6-7 week total dose 66 Gy great primary tumor . Concurrent chemotherapy consist cisplatin 100 mg/m² every 3 week 3 cycle . The primary endpoint overall survival ( OS ) . Secondary end point include failure-free survival ( FFS ) , locoregional relapse-free survival ( LRFS ) , distant metastasis-free survival ( DMFS ) , toxic effect quality life . All efficacy analysis conduct intention-to-treat population , safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Newly histologically confirm nonkeratinizing ( WHO 1991 ) nasopharyngeal carcinoma . Tumor stag T1N1M0 T2N01M0 ( 2010 UICC/AJCC stag system ) . Karnofsky scale ( KPS ) ≥ 70 . Adequate marrow : leucocyte count ≥ 4×10E9/L , hemoglobin ≥ 110g/L platelet count ≥ 100×10E9/L . Normal liver function test : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) bilirubin ≤ 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤ 2.5×ULN . Adequate renal function : creatinine clearance ≥ 60 ml/min creatinine ≤ 1.5×ULN . Patients must give write informed consent . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous radiotherapy ( except nonmelanomatous skin cancer outside intend radiotherapy volume ) . Prior radiotherapy , chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>NPC</keyword>
	<keyword>concurrent chemotherapy</keyword>
	<keyword>IMRT</keyword>
	<keyword>stage II</keyword>
</DOC>